<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251392</url>
  </required_header>
  <id_info>
    <org_study_id>UBrasilia</org_study_id>
    <nct_id>NCT02251392</nct_id>
  </id_info>
  <brief_title>Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis</brief_title>
  <acronym>ChamomillaTH</acronym>
  <official_title>Evaluation of Therapeutic Efficacy in Use of Chamomila Gel, Chamomila Infuse and Urea in Patients With Breast or Head and Neck Cancer That Developed Radiodermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Brasilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate therapeutics interventions in radiodermatitis in patients with
      breast or head and neck cancer. The data collect is going to begin after determining the
      better dose in a dose-response curve that is being conduct now in the same institution. To
      evaluate the skin reaction will be applied scale of the Radiation Therapy Oncology Group
      (RTOG) - Acute Radiation Morbidity Scoring Criteria, Common Terminology Criteria for Adverse
      Events (CTCAE) and Radiation-Induced Skin Reaction Assessment Scale (RISRAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis:

      Chamomila gel is more effective than urea (usual care); Chamomila infuse is more effective
      than urea (usual care); Chamomila gel is more effective than chamomila infuse; Chamomila
      infuse is more effective than chamomila gel; Chamomila gel is as effective than urea (usual
      care); Chamomila infuse is as effective than urea (usual care); Chamomila gel is as effective
      than chamomila infuse; Chamomila infuse is as effective than chamomila gel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of the severity of radiodermatitis, according to the RTOG score.</measure>
    <time_frame>5 weeks</time_frame>
    <description>This outcome is going to be evaluated weekly by the analisys of the signs and symptoms of radiodermititis ant the RTOG score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiation Dose</measure>
    <time_frame>5 weeks</time_frame>
    <description>radiation total dose and fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiodermititis Cure</measure>
    <time_frame>8 weeks</time_frame>
    <description>The time that pacient don´t have more the radiodermititis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reduce the severity of radiodermatitis</measure>
    <time_frame>5 weeks</time_frame>
    <description>This outcome is going to be evaluated weekly by the analisys of the time of reduce the signs and symptoms of radiodermititis ant the RTOG score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Radiodermatitis</condition>
  <arm_group>
    <arm_group_label>Chamomila recutita Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chamomila recutita Infuse 2,5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Urea cream based</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chamomila recutita Gel</intervention_name>
    <description>Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve</description>
    <arm_group_label>Chamomila recutita Gel</arm_group_label>
    <other_name>Chamomile Gel, Chamomila recutita gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chamomila recutita Infuse</intervention_name>
    <description>chamomila infuse in a concentration of 2,5% already determined in a dose response curve</description>
    <arm_group_label>Chamomila recutita Infuse 2,5%</arm_group_label>
    <other_name>Chamomile Infuse, Chamomila recutita infuse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urea cream based</intervention_name>
    <description>Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care</description>
    <arm_group_label>Urea cream based</arm_group_label>
    <other_name>Urea cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Being an adult, over the age of 18 years old; Owning diagnosis of breast or head and neck
        cancer; Being first referred to the radiotherapy protocol; Presenting radiodermatitis
        grades 1 or 2, second RTOG score, in the place where is receiving radiation therapy; No
        history of previous hypersensitivity reaction to chamomile or any plant of the Asteraceae
        or Compositae family or Urea; Demonstrate understanding to continue the intervention in
        their home environment when necessary.

        Exclusion Criteria:

        Medical prescription, during the process of data collection, some kind of intervention to
        prevent radiodermatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine B Ferreira, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Priscila MS Bontempo, Nurse</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcia A Ciol, Biostatistcs</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karine RM Silva, Nurse</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos J Sacramento, Nurse</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula ED Reis, PhD, Nurse</last_name>
    <role>Study Director</role>
    <affiliation>University of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel R Avelino, MP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Brasilia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leandro X Cardoso, Physics</last_name>
    <role>Study Chair</role>
    <affiliation>University of Brasília</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis FO Silva, MP</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Brasilia</affiliation>
  </overall_official>
  <reference>
    <citation>Reis PE, Carvalho EC, Bueno PC, Bastos JK. Clinical application of Chamomilla recutita in phlebitis: dose response curve study. Rev Lat Am Enfermagem. 2011 Jan-Feb;19(1):3-10.</citation>
    <PMID>21412623</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Brasilia</investigator_affiliation>
    <investigator_full_name>PAULA ELAINE DINIZ DOS REIS</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>chamomilla</keyword>
  <keyword>matricaria</keyword>
  <keyword>chamomile</keyword>
  <keyword>chamomila</keyword>
  <keyword>recutita</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>head and neck neoplasms</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radiodermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

